细胞色素P450 1A1和181靶向抗肿瘤前药研究进展

细胞色素P450(CYP)能催化各种内源性及外源性化合物的代谢,与多种肿瘤发生有关.其中CYP1A1参与多种前致癌物和致突变物的代谢活化,CYP1B1被认为在许多人癌细胞中特异性表达,参与药物的氧化代谢和前药的活化.CYP1A1和1B1已成为靶向抗肿瘤前药研究的新靶点.相继有大量相关研究报道,本文就近年来文献报道的CYP 1A1和1B1靶向抗肿瘤前药研究进展.     

CYP1B1酶抑制剂的最新研究进展

细胞色素P450(CYP)1B1是CYP1家族的一个亚型,参与多环芳香烃等前致癌物的代谢活化,并在17-β-雌二醇诱导的乳腺癌发生与发展过程中起到了关键性作用。该酶在肿瘤组织中的特异性高表达及在肿瘤细胞耐药中的作用,也已被大量研究证实。该酶的特异性分布及在肿瘤发生与发展中的重要地位,使得它成为抗肿瘤药物研究中的新靶点。其抑制剂研究,在肿瘤预防及克服肿瘤耐药方面具有重要意义。本文综述了近二十年来发现的CYP1B1酶的强选择性抑制剂,同时分析了它们的构效关系,对发现具有肿瘤预防及逆转肿瘤耐药作用的酶抑制剂提供了理论依据。     

细胞色素P4501B1基因多态性与乳腺癌易感性研究进展

细胞色素P450（cytochrome,CYP）1B1是P450超基因家族酶系的一个重要成员,广泛分布于肝外组织,其代谢受到外源性致癌物、雌激素等多种因素的调控。该基因存在遗传多态性,艮前已对CYP1B1基因多态性与乳腺癌易感性进行了多项研究。本文就CYP1B1基因的多态性、调控机制及其与乳腺癌的关系进行了综述。     

应用TaqMan定量方法研究巴马香猪CYP1A1、2A19、2E1 mRNA表达

目的巴马香猪是我国具有特色和优势的实验用小型猪资源品系,用于药物评价具有广阔前景。方法 以β-actin作校正,利用TaqMan定量技术对巴马香猪肝、肾、肾上腺、小肠、皮肤、脑、肺、睾丸、前列腺、子宫和卵巢等组织中CYP1A1、2A19和2E1 mRNA的表达水平进行检测,检测结果与报道的人体对应酶CYP1A2、2A6、2E1进行比较。结果巴马香猪CYP1A1、2A19、2E1 mRNA均以肝脏中最高,肝外组织明显较低,并且巴马香猪肝脏CYP1A1、2A19、2E1 mRNA均低于报道的人肝对应酶。结论巴马香猪CYP1A1、2A19、2E1与人体对应酶CYP1A2、2A6、2E1的mRNA组织表达存在一定差异,提示在其作为相应CYP亚型代谢的药物评价时应考虑这种种属差异对实验结果推广到人的影响。     

花生响应水分胁迫过程中叶片AhCYP707A1蛋白和ABA分布的变化

CYP707A蛋白是高等植物内源ABA代谢主要途径的关键酶,在水分胁迫过程中花生植株Ah CYP707A1蛋白和ABA分布与水平的变化并不清楚。研究结果表明,水分胁迫初期,花生叶片Ah CYP707A1蛋白表达均先被强烈抑制,促进ABA积累,随后蛋白表达回升,参与调节ABA稳态;叶片Ah CYP707A1蛋白以及ABA主要分布在叶片维管组织中。水分胁迫下,经CYP707A蛋白抑制剂处理后,花生叶片ABA分布和含量均有提高。抗旱花生品种‘粤油7’在水分胁迫下,Ah CYP707A1蛋白的表达以及分布均强于敏旱品种‘汕优523’,表明ABA代谢更为活跃。     

氯吡格雷对大鼠肝药物酶CYP3A4 和CYP1A2 表达的影响

目的：氯吡格雷主要由CYP3A4 催化使其激活,CYP1A2 也参与氯吡格雷活化。关于氯吡格雷对肝微粒体酶的影响国内外 文献报道不多,因此本实验通过检测肝细胞色素氧化酶CYP3A4 和CYP1A2 的表达,探讨氯吡格雷对大鼠肝药物酶的影 响。方法：生理盐水为对照组,氯吡格雷设高、中、低三个剂量组（27,13.5,6.75mg/kg/d）,雄性健康大鼠连续灌胃给药7天,脱臼处 死,取肝组织,通过western blot法检测大鼠肝脏CYP3A4 和CYP1A2 蛋白表达情况。结果：1）、氯吡格雷抑制大鼠CYP3A4 蛋白 表达,氯吡格雷高中低剂量组分别比生理盐水组大鼠CYP3A4 蛋白表达量降低（P<0.05）;氯吡格雷低中高剂量组间进行比较,大 鼠CYP3A4 蛋白表达量呈梯度减少（P<0.05）;2）、氯吡格雷抑制大鼠CYP1A2 蛋白表达,氯吡格雷高中低剂量组分别比生理盐水 组大鼠CYP1A2 蛋白表达量降低（P<0.05）,氯吡格雷低中高剂量组间进行比较,大鼠CYP1A2 蛋白表达量呈梯度减少（P<0.05）。 结论：氯吡格雷使肝细胞色素氧化酶CYP3A4 和CYP1A2 的表达量减少,因此氯吡格雷高、中、低3 个剂量组均不同程度的抑制 大鼠肝脏CYP3A4 和CYP1A2 的表达,提示当氯吡格雷与某些主要经CYP3A4 和CYP1A2 代谢的药物合用时,发生代谢性相关 作用的可能性大。     

细胞色素P450在植物三萜和甾醇骨架修饰中的功能研究进展

植物三萜类化合物在植物生长发育、抵御逆境胁迫与病虫害、生物间相互作用以及传递信息等方面发挥重要作用,植物甾醇具有重要的药用价值.细胞色素P450单加氧酶(CYP450)是参与植物代谢的最大酶家族,在三萜及甾醇骨架结构多样化及功能化修饰中具有关键作用.到目前为止,研究发现约有80个CYP450参与植物三萜代谢,包括亚家族CYP51H, CYP71A, D, CYP72A, CYP81Q, CYP87D, CYP88D, L, CYP93E, CYP705A, CYP708A和CYP716A, C, E, S, U, Y,它们参与包括特定病原体的化学防御功能和药理活性的三萜及其皂苷类化合物的代谢.亚家族CYP51G, CYP85A, CYP90B-D, CYP710A, CYP724B和CYP734A与甾醇和类固醇激素的生物合成有关.本文针对CYP450基因在三萜及甾醇化合物形成过程中不同位点的修饰功能进行概述,重点探讨了陆地植物CYP450基因11个家族的进化及在双子叶、单子叶植物中五环三萜物质合成过程中的功能.以期为充分利用具有重要价值的抗肿瘤、抗艾滋病的三萜物质的合成生物学的研究及其代谢调控提供进一步的理论依据.     

飞蝗CYP408B1和CYP409A1基因的原核表达

【目的】细胞色素P450是分布极其广泛的超家族酶,在昆虫内源及外源化合物代谢中发挥着重要的作用。本文分析了飞蝗Locusta migratoria CYP408B1和CYP409A1基因在不同组织部位的表达差异,并对两种蛋白进行原核表达,为其分子特性和生物学功能的深入研究提供基础资料。【方法】提取飞蝗5龄若虫不同组织部位的总RNA,体外反转录成c DNA,采用Real-time PCR和RT-PCR技术分析飞蝗CYP408B1和CYP409A1在不同组织部位的表达模式,构建表达载体p CW/CYP408B1、p CW/CYP409A1和p AC/CPR,将p CW/CYP408B1和p CW/CYP409A1分别与p AC/CPR在大肠杆菌Escherichia coli BL21(DE3)中进行共表达。【结果】通过PCR检测,发现CYP408B1和CYP409A1在飞蝗5龄若虫触角、脑、视叶、咽下神经节、胸神经节和附腺中均有表达,其中CYP408B1在附腺中表达量较高。原核表达结果显示,CYP409A1和CPR(NADPH细胞色素P450还原酶)均可表达,蛋白分子量分别约为58 ku和77 ku,但均为包涵体,而CYP408B1未能成功表达。【结论】本文揭示了飞蝗CYP408B1和CYP409A1在不同组织部位的表达模式,并对CYP409A1和CPR进行了原核表达,研究结果为深入探讨飞蝗细胞色素P450基因对杀虫剂的代谢解毒作用提供了实验依据和基础资料。     

飞蝗CYP408B1和CYP409A1基因的原核表达

【目的】细胞色素P450是分布极其广泛的超家族酶,在昆虫内源及外源化合物代谢中发挥着重要的作用。本文分析了飞蝗Locusta migratoria CYP408B1和CYP409A1基因在不同组织部位的表达差异,并对两种蛋白进行原核表达,为其分子特性和生物学功能的深入研究提供基础资料。【方法】提取飞蝗5龄若虫不同组织部位的总RNA,体外反转录成c DNA,采用Real-time PCR和RT-PCR技术分析飞蝗CYP408B1和CYP409A1在不同组织部位的表达模式,构建表达载体p CW/CYP408B1、p CW/CYP409A1和p AC/CPR,将p CW/CYP408B1和p CW/CYP409A1分别与p AC/CPR在大肠杆菌Escherichia coli BL21(DE3)中进行共表达。【结果】通过PCR检测,发现CYP408B1和CYP409A1在飞蝗5龄若虫触角、脑、视叶、咽下神经节、胸神经节和附腺中均有表达,其中CYP408B1在附腺中表达量较高。原核表达结果显示,CYP409A1和CPR(NADPH细胞色素P450还原酶)均可表达,蛋白分子量分别约为58 ku和77 ku,但均为包涵体,而CYP408B1未能成功表达。【结论】本文揭示了飞蝗CYP408B1和CYP409A1在不同组织部位的表达模式,并对CYP409A1和CPR进行了原核表达,研究结果为深入探讨飞蝗细胞色素P450基因对杀虫剂的代谢解毒作用提供了实验依据和基础资料。     

CYP1A1、CYP1B1、NET、DAT1单个和联合基因型与汉族人群乳腺癌易感性的研究（英文）

乳腺癌是最常见的女性癌症,其发生是遗传因素和环境因素相互作用的结果。因此,我们就CYP1A1MspⅠ(m1多态)、CYP1B1 Leu432Val、NET T-182C、DAT1-VNTR等基因多态性对新疆汉族人群乳腺癌易感性的研究进行探讨。在以144例乳腺癌患者和120例正常对照组为研究对象的病例-对照研究中,发现CYP1A1MspⅠ位点CC基因型、C等位基因(OR=3.32,95%CI:1.24~8.86;OR=1.58,95%CI:1.09~2.31)和高风险联合基因型CYP1A1 MspⅠ与CYP1B1 Leu432Val,CYP1A1 MspⅠ与DAT1-VNTR,CYP1B1 Leu432Val与DAT1-VNTR(OR=2.43,95%CI:1.23~4.78;OR=4.53,95%CI:1.26~16.27;OR=2.98,95%CI:1.10~8.06)与乳腺癌风险增加有关。CYP1B1、NET和DAT1基因多态性与乳腺癌易感性无关。这些研究结果表明,CYP1A1 MspⅠ多态性和CYP1A1、CYP1B1、DAT1高风险联合基因型能增加新疆汉族人群患乳腺癌的风险。     

Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1.

Cytochrome P450 CYP1B1 is a recently identified member of the CYP1 P450 family. We have shown that this P450 displays increased expression in several types of human cancer, indicating that CYP1B1 is a potential tumor biomarker. In this study we developed monoclonal antibodies (MAbs) to CYP1B1 that are effective on formalin-fixed, paraffin-embedded tissue sections and investigated the presence of CYP1B1 in a series of primary breast cancers. The MAbs were generated using a synthetic peptide coupled to carrier protein as the immunogen. The MAbs specifically recognized CYP1B1 and did not recognize either CYP1A1 or CYP1A2, related CYP1 forms. The MAbs were tested by immunohistochemistry and were found to be effective on formalin-fixed, paraffin-embedded tissue sections. The majority of breast cancers showed positive immunoreactivity for CYP1B1, and in each case CYP1B1 was specifically localized to tumor cells. The presence of CYP1B1 in breast cancer cells is likely to contribute to their metabolism of estradiol because CYP1B1 is a specific estradiol hydroxylase. (J Histochem Cytochem 47:1457-1464, 1999)     

Herbicide resistance of transgenic rice plants expressing human CYP1A1

Cytochrome P450 monooxygenases (P450s) metabolize herbicides to produce mainly non-phytotoxic metabolites. Although rice plants endogenously express multiple P450 enzymes, transgenic plants expressing other P450 isoforms might show improved herbicide resistance or reduce herbicide residues. Mammalian P450s metabolizing xenobiotics are reported to show a broad and overlapping substrate specificity towards lipophilic foreign chemicals, including herbicides. These P450s are ideal for enhancing xenobiotic metabolism in plants. A human P450, CYP1A1, metabolizes various herbicides with different structures and modes of herbicide action. We introduced human CYP1A1 into rice plants, and the transgenic rice plants showed broad cross-resistance towards various herbicides and metabolized them. The introduced CYP1A1 enhanced the metabolism of chlorotoluron and norflurazon. The herbicides were metabolized more rapidly in the transgenic rice plants than in non-transgenic controls. Transgenic rice plants expressing P450 might be useful for reducing concentrations of various chemicals in the environment.     

Arabidopsis CYP72C1 is an atypical cytochrome P450 that inactivates brassinosteroids

Cytochrome P450 monooxygenases (P450s) are a diverse family of proteins that have specialized roles in secondary metabolism and in normal cell development. Two P450s in particular, CYP734A1 and CYP72C1, have been identified as brassinosteroid-inactivating enzymes important for steroid-mediated signal transduction in Arabidopsis thaliana. Genetic analyses have demonstrated that these P450s modulate growth throughout plant development. While members of the CYP734A subfamily inactivate brassinosteroids through C-26 hydroxylation, the biochemical activity of CYP72C1 is unknown. Because CYP734A1 and CYP72C1 in Arabidopsis diverge more than brassinosteroid inactivating P450s in other plants, this study examines the structure and biochemistry of each enzyme. Three-dimensional models were generated to examine the substrate binding site structures and determine how they might affect the function of each P450. These models have indicated that the active site of CYP72C1 does not contain several conserved amino acids typically needed for substrate hydroxylation. Heterologous expression of these P450s followed by substrate binding analyses have indicated that CYP734A1 binds active brassinosteroids, brassinolide and castasterone, as well as their upstream precursors whereas CYP72C1 binds precursors more effectively. Seedling growth assays have demonstrated that the genetic state of CYP734A1, but not CYP72C1, affected responsiveness to high levels of exogenous brassinolide supporting our observations that CYP72C1 acts on brassinolide precursors. Although there may be some overlap in their physiological function, the distinct biochemical functions of these proteins in Arabidopsis has significant potential to fine-tune the levels of different brassinosteroid hormones throughout plant growth and development.     

Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development

Cytochrome P450s (CYPs) represent a large class of heme-containing enzymes that catalyze the metabolism of multitudes of substrates both endogenous and exogenous. Until recently, however, CYPs have been largely overlooked in cancer drug development, acknowledged only for their role in phase I metabolism of chemotherapeutics. The first successful strategy targeting CYP enzymes in cancer therapy was the development of potent inhibitors of CYP19 (aromatase) for the treatment of breast cancer. Aromatase inhibitors ushered in a new era in hormone ablation therapy for estrogen dependent cancers, and have paved the way for similar strategies (i.e., inhibition of CYP17) that combat androgen dependent prostate cancer. Identification of CYPs involved in the inactivation of anti-cancer metabolites of vitamin D(3) and vitamin A has triggered development of agents that target these enzymes as well. The discovery of the over-expression of exogenous metabolizing CYPs, such as CYP1B1, in cancer cells has roused interest in the development of inhibitors for chemoprevention and of prodrugs designed to be activated by CYPs only in cancer cells. Finally, the expression of CYPs within tumors has been utilized in the development of bioreductive molecules that are activated by CYPs only under hypoxic conditions. This review offers the first comprehensive analysis of strategies in drug development that either inhibit or exploit CYP enzymes for the treatment of cancer.     

Distinction between human cytochrome P450 (CYP) isoforms and identification of new phosphorylation sites by mass spectrometry

In mammals, Cytochrome P450 (CYP) enzymes are bound to membranes of the endoplasmic reticulum and mitochondria, where they are responsible for the oxidative metabolism of many xenobiotics as well as organic endogenous compounds. In humans, 57 isoforms were identified which are classified based on sequence homology. In the present work, we demonstrate the performance of a mass spectrometry-based strategy to simultaneously detect and differentiate distinct human Cytochrome P450 (CYP) isoforms including the highly similar CYP3A4, CYP3A5, CYP3A7, as well as CYP2C8, CYP2C9, CYP2C18, CYP2C19, and CYP4F2, CYP4F3, CYP4F11, CYP4F12. Compared to commonly used immunodetection methods, mass spectrometry overcomes limitations such as low antibody specificity and offers high multiplexing possibilities. Furthermore, CYP phosphorylation, which may affect various biochemical and enzymatic properties of these enzymes, is still poorly analyzed, especially in human tissues. Using titanium dioxide resin combined with tandem mass spectrometry for phosphopeptide enrichment and sequencing, we discovered eight human P450 phosphorylation sites, seven of which were novel. The data from surgical human liver samples establish that the isoforms CYP1A2, CYP2A6, CYP2B6, CYP2E1, CYP2C8, CYP2D6, CYP3A4, CYP3A7, and CYP8B1 are phosphorylated in vivo. These results will aid in further investigation of the functional significance of protein phosphorylation for this important group of enzymes.     

Development of a whole-cell screening system for evaluation of the human CYP1A2-mediated metabolism

Cytochrome P450 1A2 (CYP1A2) is an important member of cytochrome P450 involved in drug metabolism. In this study, a cell line, Huh7-1A2-I-E, with high expression level of CYP1A2 is established based on Huh7 cells. To achieve this, we constructed a recombinant lentiviral vector, pLenti-1A2-I-E, containing a single promoter encoding CYP1A2 followed by an internal ribosome entry site (IRES) to permit the translation of enhanced green fluorescence protein (EGFP). Such a design has greatly facilitated the selection of stable cell lines because the translations of CYP1A2 and EGFP proteins would be based on a single bi-cistronic mRNA. The Huh7-1A2-I-E cells were evaluated as a cell-based model for identification of CYP1A2 inhibitors and for studies of cytotoxicity resulted from CYP-mediated drug metabolism. Treatment of Huh7-1A2-I-E cells and the Huh7-E control cells with aflatoxin B1 showed that cells with CYP1A2 expression are much more sensitive to aflatoxin B1 and the cellular toxicity of aflatoxin B1 in Huh7-1A2-I-E cells could be prevented by furafylline, a CYP1A2 inhibitor. A collection of approximately 200 drugs were screened using this system and results indicate that for most drugs the metabolism by CYP1A2 is unlikely to have made a major contribution to the in vitro cytotoxicity except for thimerosal and evoxine. Several previously unidentified CYP1A2 inhibitors such as evoxine and berberine were also identified in this study.     

4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides as new antimitotic prodrugs activated by cytochrome P450 1A1 in breast cancer cells

The role and the importance of the sulfonate moiety in phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates (PAIB-SOs) were assessed using its bioisosteric sulfonamide equivalent leading to new cytochrome P450 1A1 (CYP1A1)-activated prodrugs designated as 4-(3-alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides (PAIB-SAs). PAIB-SAs are active in the submicromolar to low micromolar range showing selectivity toward CYP1A1-expressing MCF7 cells as compared to cells devoid of CYP1A1 activity such as MDA-MB-231 and HaCaT cells. The most potent, PAIB-SA 13, bearing a trimethoxyphenyl group on ring B blocks the cell cycle progression in G2/M phase, disrupts the microtubule dynamics and is biotransformed by CYP1A1 into CEU-638, its potent antimicrotuble counterpart. Structure-activity relationships related to PAIB-SOs and PAIB-SAs evidenced that PAIB-SOs and PAIB-SAs are true bioisosteric equivalents fully and selectively activatable by CYP1A-expressing cells into potent antimitotics.     

Differential Expression of Cytochrome P450 Enzymes in Normal and Tumor Tissues from Childhood Rhabdomyosarcoma

Intratumoral expression of genes encoding Cytochrome P450 enzymes (CYP) might play a critical role not only in cancer development but also in the metabolism of anticancer drugs. The purpose of this study was to compare the mRNA expression patterns of seven representative CYPs in paired tumor and normal tissue of child patients with rabdomyosarcoma (RMS). Using real time quantitative RT-PCR, the gene expression pattern of CYP1A1, CYP1A2, CYP1B1, CYP2E1, CYP2W1, CYP3A4, and CYP3A5 were analyzed in tumor and adjacent non-tumor tissues from 13 child RMS patients. Protein concentration of CYPs was determined using Western blot. The expression levels were tested for correlation with the clinical and pathological data of the patients. Our data showed that the expression levels of CYP1A1 and CYP1A2 were negligible. Elevated expression of CYP1B1 mRNA and protein was detected in most RMS tumors and adjacent normal tissues. Most cancerous samples exhibit higher levels of both CYP3A4 and CYP3A5 compared with normal tissue samples. Expression of CYP2E1 mRNA was found to be significantly higher in tumor tissue, however no relation was found with protein levels. CYP2W1 mRNA and/or protein are mainly expressed in tumors. In conclusion, we defined the CYP gene expression profile in tumor and paired normal tissue of child patients with RMS. The overexpression of CYP2W1, CYP3A4 and CYP3A5 in tumor tissues suggests that they may be involved in RMS chemoresistance; furthermore, they may be exploited for the localized activation of anticancer prodrugs.